New Edition of WHO TB Treatment Guidelines

world health organization
World Health Organization

The World Health Organization’s Stop TB Department has published the fourth edition of Treatment of Tuberculosis: Guidelines. The guidelines contain a number of new recommendations, including a call to discontinue regimens based on just two months of rifampicin (2HRZE/6HE). They reinforce prior WHO recommendations for drug susceptibility testing (DST) at the start of therapy for all previously treated patients, and provide guidance for appropriate treatment approaches in the light of advances in laboratory technology and the country’s progress in building laboratory capacity. They also reaffirm recommendations for supervised treatment, as well as the use of fixed-dose combinations of anti-TB drugs and patient kits as further measures for preventing the acquisition of drug resistance.

You can read the report here:

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...